Trial Profile
A phase I/II study of COL-3 [incyclinide] administered on a continuous daily oral schedule in patients with recurrent high-grade astrocytoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2013
Price :
$35
*
At a glance
- Drugs Incyclinide (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 20 Jun 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 09 Nov 2006 Status changed from in progress to completed.
- 04 Oct 2005 New trial record.